切除修复交叉互补基因1的表达与食管癌临床病理特征和术后含铂类药物辅助化疗疗效的关系

Correlation between Erccl Expression and Clinicopathological Characters and Efficacy of Postoperative Platinum-based Adjuvant Chemotherapy in Esophageal Cancer

目的:探讨食管癌组织切除修复交叉互补基因1(excision repaircross complementing 1,ERCC1)蛋白的表达与临床病理特征和术后含铂类药物辅助化疗疗效的关系。方法:选取山西省肿瘤医院2013年1月1日—2015年6月30日行手术切除的食管癌患者115例,全部病例进行肿瘤组织ERCC1表达检测,分析ERCC1表达与食管癌临床病理特征的相关性。对术后进行含铂类药物辅助化疗的62例患者进行近期疗效观察,探讨ERCC1表达与含铂类药物辅助化疗疗效的关系。结果:食管癌组织ERCCI阳性表达率为54.8%(63/115);ERCCl阳性表达的食管癌患者术后采用含铂类药物辅助化疗的1年内复发转移率为17.1%(6/35)、1年生存率为82.6%(29/35),ERCCl阴性表达的食管癌患者术后采用含铂类药物辅助化疗的1年内复发转移率为11.1%(3/27)、1年生存率为88.9%(24/27)。结论:ERCCl在食管癌组织中的表达与患者性别、年龄、部位、肿瘤长度、肿瘤组织分化程度、病理类型、淋巴结转移以及国际TNM分期无相关性。ERCC1阳性患者行含铂类药物辅助化疗后1年内复发转移率高于ERCC1阴性患者、1年生存率低于ERCC1阴性患者,提示ERCC1阴性患者可能从含铂类药物辅助化疗中获益。

ABSTRACT OBJECTIVE： To probe into the correlation between ERCC1 expression and clinicopathological characters and efficacy of postoperative platinum-based adjuvant chemotherapy in esophageal cancer. METHODS ： 115 patients with esophageal cancer accepting operation in Shanxi Tumor Hospital from Jan. 1st 2013 to Jun. 30th 2015 were selected to conduct the ERCC1 expression detection, correlation of ERCC1 expression and clinicopathological characters were analyzed. RESULTS： The positive expression of ERCC1 was 54. 8% （63/115）. The 1-year recurrence rate of positive expression of ERCC1 patients with postoperative platinum-based adjuvant chemotherapy was 17. 1% （6/35）, 1-year survival rate was 82. 6% （29/35）. And 1-year recurrence rate of negative expression of ERCC1 patients with postoperative platinum-based adjuvant chemotherapy was 11.1% （3/27）, 1-year survival Sate was 88. 9% （24/27）. CONCLUSIONS ： There are no correlation between ERCCI expression and patients gender, age, location, length of tumor, degree of tumor differentiation, pathological type, lympho node metastasis and international TNM staging system. The 1-year recurrence rate of positive expression of ERCCI patients with postoperative platinum-based adjuvant chemotherapy was higher than that of ERCCl-negative patients. Therefore, patients with ERCCl-negative esophageal cancers may benefit from platinum-based adjuvant chemotherapy.